Systemic chemotherapy as a main strategy for liver @entity3 from XXXX .

@entity1 @entity409 @entity356 @entity3
BACKGROUND: Liver metastasis is associated with poor prognosis in @entity356 . Surgical resection and systemic chemotherapy have been reported to be effective in @entity356 with @entity409 (GCLM). However, the best strategy for GCLM has not been established. METHODS: From May 2009 to July 2014, a consecutive series of GCLM @entity1 in Zhongshan Hospital of Fudan University were studied. Treatment strategies were evaluated with regard to different extents of @entity3 . RESULTS: A total of 163 @entity1 were included. The overall survival was 10.1  months. Active treatment significantly prolongs the survival of GCLM @entity1 . The overall survival time for @entity1 with liver-limited @entity3 and extra-hepatic liver @entity3 was 11.6 mo and 8.7 mo, respectively (P  =  0.012). The median survival time for liver-limited disease of H1, H2 and H3 was 14.2, 15.8, and 8.5 months, respectively (H3 vs H2, P  =  0.001; H3 vs H1, P  =  0.000; H1 vs H2, P  =  0.900). Systemic chemotherapy was chosen as the main strategy for the 'extensive' @entity1 with extra-hepatic @entity3 and H3 type liver-limited @entity3 . @entity1 ' survival was benefited by multi-line chemotherapy. No differences were shown between systemic chemotherapy and curative resection or palliative resection in H1 and H2 liver-limited @entity3 (16.0 mo vs 12.0 mo, P  =  0.711; 16.0 vs 18.8 months, P  =  0.654). CONCLUSION: Systemic chemotherapy was the main treatment for @entity356 @entity1 with liver @entity3 . Curative resection could be considered for highly selected @entity1 .
